Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V C Jordan

Showing results (161-170 of 365) with videos related to

Pageof 37
Sort By:
Seminars in Surgical Oncology|September 1, 1996
Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?M M Bilimoria, V C Jordan
Endocrinology|December 1, 1980
Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogenC J Dix, V C Jordan
British Journal of Pharmacology|November 1, 1978
The antitumour activity of tamoxifen and monohydroxytamoxifen: a comparative study in the rat [proceedings]V C Jordan, K E Naylor
British Journal of Pharmacology|August 1, 1976
Oestrogenic, anti-oestrogenic and fertility effects of some triphenylethanes and triphenylethylenes related to ethamoxytriphetol (MER 25)E R Clark, V C Jordan
Cancer Treatment and Research|May 20, 1998
The duration of adjuvant tamoxifen therapyM M Bilimoria, V C Jordan
The Journal of Endocrinology|June 1, 1980
Subcellular effects of monohydroxytamoxifen in the rat uterus: steroid receptors and mitosisC J Dix, V C Jordan
Pharmacology & Therapeutics|January 1, 1988
Metabolism of steroid-modifying anticancer agentsS P Robinson, V C Jordan
Endocrine Reviews|November 1, 1990
Endocrine pharmacology of antiestrogens as antitumor agentsV C Jordan, C S Murphy
Breast Cancer Research and Treatment|January 1, 1984
Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical studyD C Tormey, V C Jordan
Molecular and Cellular Endocrinology|July 1, 1984
Nuclear [3H]4-hydroxytamoxifen (4-OHTAM)- and [3H]estradiol (E2)-estrogen receptor complexes in the MCF-7 breast cancer and GH3 pituitary tumor cell linesA C Tate, V C Jordan
Pageof 37

Showing results (161-170 of 365) with videos related to

Sort By:
Pageof 37
Seminars in Surgical Oncology|September 1, 1996
Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?M M Bilimoria, V C Jordan
Endocrinology|December 1, 1980
Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogenC J Dix, V C Jordan
British Journal of Pharmacology|November 1, 1978
The antitumour activity of tamoxifen and monohydroxytamoxifen: a comparative study in the rat [proceedings]V C Jordan, K E Naylor
British Journal of Pharmacology|August 1, 1976
Oestrogenic, anti-oestrogenic and fertility effects of some triphenylethanes and triphenylethylenes related to ethamoxytriphetol (MER 25)E R Clark, V C Jordan
Cancer Treatment and Research|May 20, 1998
The duration of adjuvant tamoxifen therapyM M Bilimoria, V C Jordan
The Journal of Endocrinology|June 1, 1980
Subcellular effects of monohydroxytamoxifen in the rat uterus: steroid receptors and mitosisC J Dix, V C Jordan
Pharmacology & Therapeutics|January 1, 1988
Metabolism of steroid-modifying anticancer agentsS P Robinson, V C Jordan
Endocrine Reviews|November 1, 1990
Endocrine pharmacology of antiestrogens as antitumor agentsV C Jordan, C S Murphy
Breast Cancer Research and Treatment|January 1, 1984
Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical studyD C Tormey, V C Jordan
Molecular and Cellular Endocrinology|July 1, 1984
Nuclear [3H]4-hydroxytamoxifen (4-OHTAM)- and [3H]estradiol (E2)-estrogen receptor complexes in the MCF-7 breast cancer and GH3 pituitary tumor cell linesA C Tate, V C Jordan
Pageof 37